Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Abstract CT105: Preliminary results from the Phase I part of a first-in-human Phase I/II study of HH2853, an EZH1/2 inhibitor, in patients with relapsed/refractory non-Hodgkin lymphomas or advanced solid tumors
Fan, Zhengfu , Fang, Meiyu , Patrick, Johnston, Tun, Han, Sommerhalder, David , Gong, Jifang , Yang, Yun , Song, Yuqin , Li, Xianan , Ma, Qiuying, Zhu, Jun , Wang, Jin , Patrick, Johnston, Yang, Jilong , Muñoz, Javier , Li, Zhiming , Han, Jinming , Shen, Lin

Mayo Clinic

Cancer Research | April 14, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: CT105-CT105

10.1158/1538-7445.am2023-ct105 Get It

Abstract Background: The dysregulation of polycomb repressive complex 2 (PRC2) promotes tumorigenesis and progression. Two therapeutic agents targeting enhancer of zeste homolog (EZH) 2 or EZH1/2, the catalytic subunits of PRC2, have been approved in several cancer types. HH2853 is a novel selective EZH1/2 dual inhibitor, which has demonstrated superior anti-tumor efficacy to tazemetostat (EZH2 inhibitor approved by FDA) in various preclinical models. Methods: This is a first-in-human, open-label, multi-center, phase (Ph) I/II study of HH2853 in patients (pts) with relapsed/refractory (r/r) non-Hodgkin lymphomas (NHLs) or advanced solid tumors. HH2853 was administered orally twice daily (BID) on a continuous 28-day treatment cycle. Ph I consist of two parts: dose escalation part adopting accelerated titration followed by a Bayesian optimal interval design and dose extension part. Dose limiting toxicity (DLT) was evaluated during the 1st cycle in dose escalation. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of HH2853 were explored in this Ph I study. Results: As of Oct 19, 2022, a total of 57 pts, including 50 pts with solid tumors and 7 pts with r/r follicular lymphoma (FL), were enrolled from 12 sites in China and the US. Twenty-five (43.9%) pts received ≥3 lines of prior systemic therapies. Six dose levels(50 mg, 100 mg, 200 mg, 400 mg, 600 mg and 800 mg)were evaluated. DLTs were observed in 2 of 8 DLT evaluable pts at 800 mg: one grade 3 platelet count decreased and one grade 3 diarrhea. A conclusive maximal tolerated dose was not reached. The most common treatment-related adverse events (TRAE) were diarrhea (45.6%), blood bilirubin increased (35.1%), white blood cell count (WBC) decreased (26.3%), platelet count decreased (26.3%), rash (24.6%) and anemia (22.8%). The most common ≥grade 3 TRAEs included anemia (8.8%), platelet count decreased (7.0%), WBC decreased (5.3%) and diarrhea (5.3%). TRAEs leading to dose interruption or reduction were reported in 17.5% and 8.8% pts respectively. No TRAE led to dose discontinuation or death. PK data indicated dose-related increase in exposure from 50 to 600 mg. PD data showed a significant inhibition (maximum reached >90%) of H3K27me3 in granulocytes and monocytes at 400-800 mg. Tumor responses were observed in 7 pts from 200 to 800 mg in multiple tumor types, including complete response in 1 patient with FL, partial response in 3 pts with epithelioid sarcoma, 2 pts with FL and 1 patient with malignant rhabdoid tumor of pancreas. Conclusions: This first-in-human study of HH2853 showed a manageable safety profile and promising anti-tumor activity in multiple tumor types, supporting further exploration in NHLs and solid tumors after recommended Ph II dose is determined.Clinical trial information: NCT04390737 Citation Format: Zhengfu Fan, Jin Wang, Meiyu Fang, Johnston Patrick, Tun Han, David Sommerhalder, Jifang Gong, Jilong Yang, Yun Yang, Javier Munoz, Yuqin Song, Zhiming Li, Xian'an Li, Qiuying Ma, Jinming Han, Lin Shen, Jun Zhu. Preliminary results from the Phase I part of a first-in-human Phase I/II study of HH2853, an EZH1/2 inhibitor, in patients with relapsed/refractory non-Hodgkin lymphomas or advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT105.
Determinants of physician assessment of chronic rhinosinusitis disease control using EPOS 2020 criteria and the importance of incorporating patient perspectives of disease control
Sedaghat, Ahmad R. , Caradonna, David S., Franzese, Christine B., Gray, Stacey T. , Halderman, Ashleigh A. , Hopkins, Claire , Lee, Jivianne T. , McCoul, Edward D. , O’Brien, Erin K. , Pynnonen, Melissa A., Wise, Sarah K. , Woodworth, Bradford A. , Phillips, Katie M. , Hopkins, Claire , Kuan, Edward C , McCoul, Edward D , Wang, Eric W , Woodworth, Bradford A , Yao, William C , O'Brien, Erin K , Chandra, Rakesh Kumar , Pletcher, Steven D. , Yao, William C.

Mayo Clinic

International Forum of Allergy & Rhinology | April 12, 2023 | Volume: 13 | Issue: 11 | Pages: 2004-2017

10.1002/alr.23168 | PMID 37042828 Get It

AbstractBackgroundWe identify chronic rhinosinusitis (CRS) manifestations associated with how rhinologists assess CRS control, with a focus on patient perspectives (patient‐reported CRS control).MethodsFifteen rhinologists were provided with real‐world data from 200 CRS patients. Participating rhinologists first classified patients’ CRS control as “controlled,” “partly controlled,” and “uncontrolled” using seven CRS manifestations reflecting European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) CRS control criteria (nasal obstruction, drainage, impaired smell, facial pain/pressure, sleep disturbance, use of systemic antibiotics/corticosteroids in past 6 months, and nasal endoscopy findings) and patient‐reported CRS control. They then classified patients’ CRS control without knowledge of patient‐reported CRS control. Interrater reliability and agreement of rhinologist‐assessed CRS control with patient‐reported CRS control and EPOS guidelines were determined.ResultsCRS control classification with and without knowledge of patient‐reported CRS control was highly consistent across rhinologists (κw = 0.758). Rhinologist‐assessed CRS control agreed with patient‐reported CRS control significantly better when rhinologists had knowledge of patient‐reported CRS control (κw = 0.736 vs. κw = 0.554, p < 0.001). Patient‐reported CRS control, nasal obstruction, drainage, and endoscopy findings were most strongly associated with rhinologists’ assessment of CRS control. Rhinologists’ CRS control assessments weakly agreed with EPOS CRS control guidelines with (κw = 0.529) and without (κw = 0.538) patient‐reported CRS control. Rhinologists classified CRS as more controlled than EPOS guidelines in almost 50% of cases.ConclusionsThis study directly demonstrates the importance of patient‐reported CRS control as a dominant influence on rhinologists’ CRS control assessment. Knowledge of patient‐reported CRS control may better align rhinologists’ CRS control assessments and treatment decisions with patients’ perspectives.
Unknown Causes of Death in Cancer Patients
Chinniah, Siven, Chiam, Mckenzee , Mani, Kyle , Liang, Menglu , Prasad, Vinayak K., Zaorsky, Nicholas G , Trifiletti, Daniel M. , Spratt, Daniel E. , Wang, Ming , Tchelebi, Leila T. , Zaorsky, Nicholas G.

Mayo Clinic

American Journal of Clinical Oncology | April 11, 2023 | Volume: 46 | Issue: 6 | Pages: 246-253

10.1097/coc.0000000000001003 | PMID 37038261 Get It

Objectives: Deaths from an unknown cause are difficult to adjudicate and oncologic studies of comparative effectiveness often demonstrate inconsistencies in incorporating these deaths and competing events (eg, heart disease and stroke) in their analyses. In this study, we identify cancer patients most at risk for death of an unknown cause. Methods: This retrospective, population-based study used cancer registry data from the Surveillance, Epidemiology, and End Results database (1992-2015). The absolute rate of unknown causes of death (COD) cases stratified by sex, marital status, race, treatment, and cancer site were calculated and a multivariable logistic regression model was applied to obtain adjusted odds ratios with 95% CIs. Results: Out of 7,154,779 cancer patients across 22 cancer subtypes extracted from Surveillance, Epidemiology, and End Results, 3,448,927 died during follow-up and 276,068 (7.4%) of these deaths were from unknown causes. Patients with an unknown COD had a shorter mean survival time compared with patients with known COD (36.3 vs 65.7 mo, P < 0.001). The contribution of unknown COD to total mortality was highest in patients with more indolent cancers (eg, prostate [12.7%], thyroid [12.3%], breast [10.7%]) and longer follow-up (eg, >5 to 10 y). One, 3, and 5-year cancer-specific survival (CSS) calculations including unknown COD were significantly decreased compared with CSS estimates excluding cancer patients with unknown COD. Conclusion: Of the patients, 7.4% died of unknown causes during follow-up and the proportion of death was higher with longer follow-up and among more indolent cancers. The attribution of high percentages of unknown COD to cancer or non-cancer causes could impact population-based cancer registry studies or clinical trial outcomes with respect to measures involving CSS and mortality.
STAT2 hinders STING intracellular trafficking and reshapes its activation in response to DNA damage
Wang, Chenyao , Holvey-Bates, Elise, Wightman, Samantha M. , Latif, Muhammad-Bilal, Zhao, Junjie , Li, Xiaoxia , Sen, Ganes C. , Stark, George R. , Wang, Yuxin , Wightman, Samantha , Sen, Ganes C , Stark, George R , Wang, Yuxin , Jing, Nan , Chen, Xing

Mayo Clinic

Proceedings of the National Academy of Sciences | April 10, 2023 | Volume: 120 | Issue: 16 | Pages: No page available

10.1073/pnas.2216953120 | PMID 37036972 Get It

In cancer cells, endogenous or therapy-induced DNA damage leads to the abnormal presence of DNA in the cytoplasm, which triggers the activation of cGAS (cyclic GMP–AMP synthase) and STING (stimulator of interferon genes). STAT2 suppresses the cGAMP-induced expression of IRF3-dependent genes by binding to STING, blocking its intracellular trafficking, which is essential for the full response to STING activation. STAT2 reshapes STING signaling by inhibiting the induction of IRF3-dependent, but not NF-κB–dependent genes. This noncanonical activity of STAT2 is regulated independently of its tyrosine phosphorylation but does depend on the phosphorylation of threonine 404, which promotes the formation of a STAT2:STING complex that keeps STING bound to the endoplasmic reticulum (ER) and increases resistance to DNA damage. We conclude that STAT2 is a key negative intracellular regulator of STING, a function that is quite distinct from its function as a transcription factor.
Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America
Khalili, Mandana , Leonard, Kelsey R., Roberts, Lewis R. , Sterling, Richard K. , Belle, Steven H., Lau, Daryl , Chung, Raymond , Bisceglie, Adrian M. Di , Lisker‐Melman, Mauricio , Juan, Joshua, Yim, Colina, Lee, William M. , Murakam, Carol S., Perrillo, Robert, Do, Son , Han, Steven‐Huy B. , Tran, Tram T. , Cooper, Stewart , Tsai, Naoky, Younoszai, Barak, Fried, Michael, Darling, Jama M., Carithers, Robert C., Shuhart, Margaret C., Wang, Chia C. , Luketic, Velimir A. , Hoofnagle, Jay H., Doo, Edward , Park, Jang‐June , Roberts, Lewis R , Khalili, Mandana , Ghany, Marc G. , Hassan, Mohamed Ahmed Salih , Lok, Anna S. , Janssen, Harry L.A. , Wong, David , Feld, Jordan J. , Terrault, Norah A. , Fontana, Robert J. , Muir, Andrew Joseph , Evon, Donna M. , Kowdley, Kris V. , Liang, T. Jake , Chang, Kyong‐Mi , Wahed, Abdus S. , King, Wendy C. , Kleiner, David Erwin

Mayo Clinic

JAMA Network Open | April 10, 2023 | Volume: 6 | Issue: 4 | Pages: e237018

10.1001/jamanetworkopen.2023.7018 | PMID 37036707 Get It

ImportanceDisparities in treatment initiation may affect outcomes, but data on racially diverse populations with chronic hepatitis B virus (HBV) infection are limited.ObjectiveTo examine whether HBV treatment initiation and outcomes differ among racial groups.Design, Setting, and ParticipantsFrom January 14, 2011, to January 28, 2018, hepatitis B surface antigen—positive adults (age ≥18 years) not receiving anti-HBV therapy were enrolled and followed up at weeks 12, 24, and every 24 weeks thereafter in a multicenter longitudinal cohort study (Hepatitis B Research Network [HBRN] adult cohort study) conducted in North America. The last study visit and data collection were completed January 28, 2019. Data were analyzed from August 27, 2021, to August 25, 2022. All HBRN participants were included unless they had acute HBV, HIV, hepatitis C or D, less than 24-weeks of follow-up after enrollment, initiated treatment at or immediately after enrollment, or had unknown race.ExposuresParticipants had clinical and laboratory assessments and could receive anti-HBV treatment after enrollment.Main Outcomes and MeasuresHepatitis B virus treatment initiation and major adverse liver outcomes (hepatic decompensation, hepatocellular carcinoma, liver transplant, and death).ResultsOf 1550 participants, 193 (12%) were African American or Black, 1157 (75%) were Asian, 157 (10%) were White, and 43 (3%) were other races; 789 (51%) were women, and the median age was 41.2 (IQR, 32.9-51.6) years. Sociodemographic and virologic parameters differed between groups. During 5727 person-years of follow-up, 504 participants initiated treatment, with incidences of 4.8 per 100 person-years in African American or Black individuals, 9.9 per 100 person-years in Asian individuals, 6.6 per 100 person-years in White individuals, and 7.9 per 100 person-years in those of other races (P &amp;lt; .001). A lower proportion (14%) of African American or Black participants met treatment criteria compared with Asian (22%) and White (27%) individuals (P = .01). The cumulative probabilities of treatment initiation after meeting the criteria were not significantly different among racial groups (African American or Black, 0.45; Asian, 0.38; White, 0.40 at 48 weeks and African American or Black, 0.45; Asian, 0.51; White, 0.51 at 72 weeks; P = .68). The incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.Conclusions and RelevanceIn this observational study of chronic HBV, African American or Black participants were less likely than individuals of other races to meet treatment criteria, but among those who did, HBV treatment receipt did not differ significantly by race or socioeconomic factors. Not all eligible participants initiated treatment, but adverse liver outcomes were rare. These findings may not be generalizable to patients with chronic HBV receiving care in other settings.
Neoadjuvant Therapy Regimens for Hilar Cholangiocarcinoma Before Liver Transplant
Keltner, Samuel J. , Hallemeier, Christopher L. , Tao, Randa , Kharofa, Jordan , Hallemeier, Christopher, Tao, Randa , Hallemeier, Christopher Leigh , Wang, Kyle , Shah, Shimul A. , Heimbach, Julie K.

Mayo Clinic

American Journal of Clinical Oncology | April 10, 2023 | Volume: 46 | Issue: 6 | Pages: 276-278

10.1097/coc.0000000000001002 | PMID 37036238 Get It

Objectives: Patients with unresectable hilar cholangiocarcinoma (hCCA) may be eligible for curative treatment through liver transplantation (LT). Neoadjuvant protocols often include radiotherapy (RT), however, there is no standard RT approach. The purpose of this study is to characterize practice patterns of RT use before transplantation for hCCA. Methods: A survey was administered to radiation oncologists practicing at LT centers identified through the U.S. Organ Procurement and Transplant Network and the International Cholangiocarcinoma Research Network. The survey consisted of 13 questions regarding RT details as well as approaches to systemic therapy. For cross-regimen comparison, the cumulative RT tumor dose was standardized using the EQD2 method. Results: Twenty-three centers utilizing neoadjuvant therapy for hCCA were identified. Most respondents (96%) use both chemotherapy and RT as part of their protocol. Elective nodal volumes commonly included the portal vein lymph nodes (91%) and celiac artery lymph nodes (70%). After an initial 45 Gy plan, a wide range of sequential boost regimens was used. The median cumulative dose including boosts to the gross disease was 58 Gy (EQD2) with a wide range of 40 to 110 Gy. Five (22%) include brachytherapy as part of their treatment plan. The majority (96%) used concurrent chemotherapy with fluoropyrimidines. Conclusions: These results suggest significant variability of neoadjuvant RT use for hCCA before LT. A wide range of doses and fractionation schemes are utilized with cumulative doses ranging from 40 to 110 Gy (EQD2). A further study evaluating the efficacy and toxicity of these various approaches is warranted to better inform best practices.
Review of management options for mantle cell lymphoma in pregnancy
Ng, Wern Lynn , Bock, Allison M. , Wang, Michael , Nowakowski, Grzegorz S. , Wang, Yucai , Jevremović, Dragan

Mayo Clinic

Leukemia & Lymphoma | April 10, 2023 | Volume: 64 | Issue: 6 | Pages: 1194-1198

10.1080/10428194.2023.2196592 | PMID 37035894 Get It

LRP1 in vascular mural cells modulates cerebrovascular integrity and function in the presence of APOE4
Oue, Hiroshi , Yamazaki, Yu , Qiao, Wenhui , Yuanxin, Chen, Ren, Yingxue , Kurti, Aishe, Shue, Francis , Parsons, Tammee M., Perkerson, Ralph B., Kawatani, Keiji , Wang, Ni , Starling, Skylar C , Mosneag, Ioana‐Emilia , Aikawa, Tomonori , Holm, Marie‐Louise , Liu, Chia‐Chen , Inoue, Yasuteru , Sullivan, Patrick M. , Asmann, Yan W. , Bu, Guojun , Kanekiyo, Takahisa , Liu, Chia-Chen , Bu, Guojun , Shue, Francis , Yuanxin, Chen, Roy, Bhaskar, Kim, Betty Y.S. , Yamazaki, Yu

Mayo Clinic

JCI Insight | April 9, 2023 | Volume: 8 | Issue: 7 | Pages: No page available

10.1172/jci.insight.163822 | PMID 37036005 Get It

Cerebrovasculature is critical in maintaining brain homeostasis; its dysregulation often leads to vascular cognitive impairment and dementia (VCID) during aging. VCID is the second most prevalent cause of dementia in the elderly, after Alzheimer’s disease (AD), with frequent cooccurrence of VCID and AD. While multiple factors are involved in the pathogenesis of AD and VCID, APOE4 increases the risk for both diseases. A major apolipoprotein E (apoE) receptor, the low-density lipoprotein receptor-related protein 1 (LRP1), is abundantly expressed in vascular mural cells (pericytes and smooth muscle cells). Here, we investigated how deficiency of vascular mural cell LRP1 affects the cerebrovascular system and cognitive performance using vascular mural cell–specific Lrp1 -KO mice ( smLrp1 –/– ) in a human APOE3 or APOE4 background. We found that spatial memory was impaired in the 13- to 16-month-old APOE4 smLrp1 –/– mice but not in the APOE3 smLrp1 –/– mice, compared with their respective littermate control mice. These disruptions in the APOE4 smLrp1 –/– mice were accompanied with excess paravascular glial activation and reduced cerebrovascular collagen IV. In addition, blood-brain barrier (BBB) integrity was disrupted in the APOE4 smLrp1 –/– mice. Together, our results suggest that vascular mural cell LRP1 modulates cerebrovasculature integrity and function in an APOE genotype–dependent manner.
Provisional practice recommendation for the management of myopathy in VCP‐associated multisystem proteinopathy
Roy, Bhaskar , Peck, Allison , Evangelista, Teresinha , Díaz‐Manera, Jordi , Korb, Manisha Kak , Wicklund, Matthew , Milone, Margherita , Freimer, Miriam , Kushlaf, Hani , Villar‐Quiles, Rocío‐Nur , Stojkovic, Tanya , Needham, Merrilee , Palmio, Johanna , Keung, Benison , Mozaffar, Tahseen , Weihl, Conrad C. , Kimonis, Virginia , Milone, M , Díaz-Manera, Jordi , Pfeffer, Gerald , Wang, Leo L. , Lloyd, Thomas E , Roy, Bhaskar

Mayo Clinic

Annals of Clinical and Translational Neurology | April 7, 2023 | Volume: 10 | Issue: 5 | Pages: 686-695

10.1002/acn3.51760 | PMID 37026610 Get It

AbstractValosin‐containing protein (VCP)‐associated multisystem proteinopathy (MSP) is a rare genetic disorder with abnormalities in the autophagy pathway leading to various combinations of myopathy, bone diseases, and neurodegeneration. Ninety percent of patients with VCP‐associated MSP have myopathy, but there is no consensus‐based guideline. The goal of this working group was to develop a best practice set of provisional recommendations for VCP myopathy which can be easily implemented across the globe. As an initiative by Cure VCP Disease Inc., a patient advocacy organization, an online survey was initially conducted to identify the practice gaps in VCP myopathy. All prior published literature on VCP myopathy was reviewed to better understand the different aspects of management of VCP myopathy, and several working group sessions were conducted involving international experts to develop this provisional recommendation. VCP myopathy has a heterogeneous clinical phenotype and should be considered in patients with limb‐girdle muscular dystrophy phenotype, or any myopathy with an autosomal dominant pattern of inheritance. Genetic testing is the only definitive way to diagnose VCP myopathy, and single‐variant testing in the case of a known familial VCP variant, or multi‐gene panel sequencing in undifferentiated cases can be considered. Muscle biopsy is important in cases of diagnostic uncertainty or lack of a definitive pathogenic genetic variant since rimmed vacuoles (present in ~40% cases) are considered a hallmark of VCP myopathy. Electrodiagnostic studies and magnetic resonance imaging can also help rule out disease mimics. Standardized management of VCP myopathy will optimize patient care and help future research initiatives.
Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
Matin, Aasiya , Inwards, David J. , Micallef, Ivana N. , Johnston, Patrick B. , Porrata, Luis F. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Micallef, Ivana, Porrata, Luis, Tun, Aung M. , Wang, Yucai , Habermann, Thomas M. , Paludo, Jonas , Villasboas, José C. , Rosenthal, Allison , Tun, Han W. , Cerhan, James R. , Witzig, Thomas E.

Mayo Clinic

HemaSphere | April 5, 2023 | Volume: 7 | Issue: 4 | Pages: e869

10.1097/hs9.0000000000000869 | PMID 37034004 Get It

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack of randomized controlled trials. Clinical characteristics and outcomes of 115 patients with relapse (or progression) after ASCT are studied. After a median follow-up of 8.59 years from post-ASCT relapse, the median progression-free survival (PFS) and overall survival (OS) were 0.91 and 5.07 years, respectively. Median lines of therapy after post-ASCT relapse was 2 (range, 1–12). The median PFS was not reached (NR) versus 1.11 versus 0.50 versus 0.85 versus 0.78 years (P = 0.006) and OS was NR versus 7.60 versus 3.08 versus 3.51 versus 3.17 years (P = 0.28) in patients first treated with ICIs versus BV versus investigational agents versus chemotherapy versus radiation therapy (RT). First-line treatment with novel agents (ie, ICIs and BV) was associated with superior outcomes compared with investigational agents and chemotherapy/RT with a median PFS of 1.65 versus 0.50 versus 0.79 years (P = 0.003) and a median OS of 7.60 versus 3.08 versus 3.32 years (P = 0.08). Regardless of lines of therapy, the treatment with ICIs had the most favorable outcome with a median PFS and OS of 3.98 and NR years, respectively. Allogeneic stem cell transplant (allo-SCT) was done in 23 patients (20%), and the median post-allo-SCT PFS and OS were 1.31 and 2.35 years, respectively. In conclusion, survival following post-ASCT relapse improves significantly when patients receive novel agents.